Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204085 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT02204085: Active Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, sponsored by Beth Israel Deaconess Medical Center.
NCT02204085 is a Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 33 participants, below the 53-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02204085, a Phase 1 study of Recurrent Adult Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.
Primary Outcome
Phase I: Maximum Tolerated Dose of GO-203-2c
Conditions Studied
Interventions
- DRUG GO-203-2c
- DRUG GO-203-2c + Decitabine
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT02204085 still lists
NCT02204085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 53-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with Recurrent Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which GO-203-2c is the first listed.
NCT02204085 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02204085 about?
NCT02204085 is a clinical study titled "A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia". This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I cli...
What is the current status of trial NCT02204085?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2014-09. Estimated completion is 2025-12.
What conditions does trial NCT02204085 study?
This clinical trial studies the following conditions: Recurrent Adult Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse.
What interventions are being tested in trial NCT02204085?
The interventions under investigation include: GO-203-2c (DRUG), GO-203-2c + Decitabine (DRUG).
Who is sponsoring clinical trial NCT02204085?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02204085 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02204085's enrollment target sits among peer trials
33 10th of 19 higher than 10 of 19 other Recurrent Adult Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
RECRUITING · Phase 1
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia